Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128393 | 0.78 | HTT (0.47) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL959784 | 0.77 | MEN1 (0.37) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL535681 | 0.77 | HTT (0.36) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL877521 | 0.77 | CRBN (0.35) | MEN1KMT2AHTTNPSR1CRBN | |
| SCHEMBL3024635 | 0.74 | SMN1; SMN2 (0.35) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL16125119 | 0.74 | SORD (0.37) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL14901206 | 0.74 | HTT (0.34) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL2158360 | 0.74 | HTT (0.34) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL16125118 | 0.73 | HTT (0.33) | MEN1KMT2AHTTSMN1; SMN2NPSR1 | |
| SCHEMBL4650978 | 0.72 | SMN1; SMN2 (0.39) | MEN1KMT2AHTTSMN1; SMN2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617791-B2 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4230628-B1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4230628-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230628-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022078480-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2022-04-21 | — | — | WO | disclosed |
| CN-114369096-A | Triheterocyclic derivatives, pharmaceutical compositions and uses thereof | 上海迪诺医药科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617791-B2 | Triheterocyclic derivative, and pharmaceutical composition and application thereof | ATR, NR3C1, NR5A1 | MEN1 2709/4885KMT2A 2738/4885HTT 3449/4885 |
| US-20240025899-A1 | TRIHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ATR, ATRIP, CHEK2 | MEN1 2501/4885KMT2A 2303/4885HTT 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.